Serum Her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer

Simple item page
dc.contributor.authorGoksel G.
dc.contributor.authorTaneli F.
dc.contributor.authorUslu R.
dc.contributor.authorUlman C.
dc.contributor.authorDinc G.
dc.contributor.authorCoskun T.
dc.contributor.authorKandiloglu A.R.
dc.date.accessioned2024-07-22T08:23:13Z
dc.date.available2024-07-22T08:23:13Z
dc.date.issued2007
dc.description.abstractThis study was conducted to investigate the serum levels of her-2/neu and survivin in patients with early-stage breast cancer and their relationship with known histological parameters. Forty-one patients with early-stage breast cancer were investigated. Serum samples were collected from patients on their first admission before adjuvant chemotherapy, and from healthy controls. Serum her-2/neu and survivin levels were determined using an enzyme-linked immunosorbent assay. There was no difference in the levels of serum her-2/neu and survivin between the breast cancer patients and the control group. Serum her-2/neu concentration showed moderate correlations with disease stage and the Ki-67 level, and the serum survivin level showed a moderate correlation with progesterone receptor concentration. Serum levels of her-2/neu and survivin were not significantly related to age and histological parameters in patients with early-stage breast cancer. However, much research continues on the prognostic value of serum her-2/neu and survivin levels, and important new knowledge may ultimately emerge. Copyright © 2007 Cambridge Medical Publications.
dc.identifier.DOI-ID10.1177/147323000703500201
dc.identifier.issn03000605
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19443
dc.language.isoEnglish
dc.publisherCambridge Medical Publications
dc.subjectepidermal growth factor receptor 2
dc.subjectKi 67 antigen
dc.subjectprogesterone receptor
dc.subjectsurvivin
dc.subjectadult
dc.subjectage
dc.subjectarticle
dc.subjectbreast cancer
dc.subjectcancer adjuvant therapy
dc.subjectcancer chemotherapy
dc.subjectcancer staging
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectearly cancer
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectprotein blood level
dc.titleSerum Her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer
dc.typeArticle

Files

Collections

Scopus Koleksiyonu